PSIVIDA (Stock Symbol: PSDV)
PSDV- Stock Profile
|Stock Ticker (Symbol):||PSDV|
|Traded Exchange:||NASDAQ Stock Exchange|
|Average Traded Price:||$4.45|
|Average Daily Traded Volume:||113,400|
|Started to Trade on:||Thursday, January 27, 2005|
pSivida Corp., together with its subsidiaries, develops drug delivery products that are administered by implantation, injection, or insertion. The company's lead product candidate is Iluvien, which is in Phase III clinical trials and delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), a cause of vision loss. It is also conducting Phase II clinical trials with Iluvien in wet and dry age-related macular degeneration. In addition, the company's products include Retisert, an intravitreal drug implant for the treatment of chronic non-infectious posterior uveitis; and Vitrasert for cytomegalovirus retinitis, a blinding eye disease that occurs in individuals with advanced AIDS. It is developing a series of additional miniaturized, bioerodible technologies, including BioSilicon technology, which is nano-structured porous silicon designed for use as a drug delivery platform; and Medidur technology, a miniaturized, injectable, sustained-release drug delivery system to advance the treatment of medical conditions in critical areas, such as ophthalmology, oncology, and cardiology. Further, the company's BioSilicon product candidates includes BrachySil, a brachytherapy product in development for the treatment of solid tumors; and completed an initial safety study of BrachySil for the treatment of pancreatic cancer and a dose ranging study. It has strategic collaborations with Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.